TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that sarcopenia should be understood as a problem involving the aging motor system, not muscle alone. The authors say the wider view could guide assessment and research, but proposed tests and their effects still need validation.
A paper in The Lancet Healthy Longevity argues that weakness and mobility loss in older adults cannot be explained by muscle decline alone, proposing that sarcopenia be understood as a disorder of the aging motor system. The authors say the broader model could change how clinicians assess weakness and how researchers test treatments, although the proposed approach has not yet been shown to improve patient outcomes.
Sarcopenia is commonly associated with the age-related loss of muscle, strength and physical function. The Medical Xpress report says it affects up to 29% of older adults living in the community, with higher rates among people in hospitals and residential care and among those with multiple health conditions or frailty. It is linked to disability and loss of independence, while falls are a major concern: Australia recorded 253,800 fall-related hospitalizations in 2024–25. The report also cites 6,722 deaths following falls in the preceding year and an estimated $5.4 billion in health-system costs from fall injuries.
In their paper, Lucas B. R. Orssatto and colleagues argue that the clinical definition has already moved beyond muscle size. Measures such as grip strength, walking speed and chair stands are used because they can indicate function and predict outcomes better than muscle mass alone, according to the report. But the authors say explanations and treatment strategies have often continued to focus primarily on muscle.
The proposed wider view includes the brain, spinal cord, nerves and their connections to muscle. The authors describe how changes in movement planning, nerve signaling, balance and position sense may contribute to weakness and slower movement. They point to chair rising as an example: getting up quickly requires power and coordination, not just muscle bulk. The paper calls for diagnostic working groups to consider this model and for more research measuring nerve and muscle function together.
The proposal could matter because a person’s muscle mass may not explain how well they can walk, rise from a chair or maintain balance. If weakness is assessed only as muscle loss, clinicians and researchers may miss other contributors to mobility problems. The authors argue that examining movement and motor control could help distinguish among causes and inform more targeted care.
The issue has practical stakes for older adults, whose declining strength and mobility can increase the risk of falls and threaten independence in everyday activities. A wider model could also influence which outcomes count in treatment research. The report notes that strategies that increase muscle do not always produce comparable improvements in what a person can do, while exercise can improve strength and mobility even when muscle mass does not measurably change.
That does not establish that a motor-system approach will prevent falls or outperform current care. The authors acknowledge that the proposed measures have not been proven better than existing screening methods on outcomes or cost. The near-term significance is a research and clinical question: whether assessment that looks beyond muscle can lead to better decisions and functional results.
Products Worth Considering
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Assessment Has Shifted
For years, sarcopenia was often framed chiefly as muscle wasting. According to the Medical Xpress report, diagnostic practice has increasingly emphasized strength and physical performance rather than muscle mass alone. Grip strength, gait speed and chair-stand performance are among the measures used to assess function.
In Australia, primary care has also received new guidance. Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm for screening, assessing and managing poor muscle health in primary care, the report says. The new paper builds on that clinical focus but challenges the assumption that reduced muscle is the main explanation for weakness.
The article’s authors recommend clinicians pay attention to how quickly a patient rises from a chair, steadiness during sustained effort, hand dexterity and changes in walking when a person is asked to talk at the same time. They also say that weakness that is asymmetric, rapid or out of proportion to muscle loss warrants closer examination. The report notes that sedative and anticholinergic medicines can blunt motor drive, making medication review relevant to assessment.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and colleagues, authors of the paper in The Lancet Healthy Longevity
Tests and Outcomes Still Need Validation
The paper presents a proposed framework, not evidence that the suggested assessment measures improve care. The authors say it has not been established whether these measures outperform existing screens in patient outcomes or cost. It is also unclear which tests would be practical for routine primary care, particularly because access to neuromuscular expertise is uneven.
The report does not provide trial results showing that treatments targeting the wider motor system prevent falls, preserve independence or work better than current approaches. Nor does it establish how much each part of the motor system contributes to weakness in an individual patient. Those questions require validation studies and clinical trials, which the authors say should measure nerve as well as muscle function.
Research Must Test the Wider Model
The authors call for international groups that set sarcopenia diagnostic criteria to consider their proposed five-point agenda. They also want investment in practical tests that can be validated for clinical use, guidelines supporting a staged assessment approach, and trials that assess both neuromuscular function and muscle.
For now, the paper does not replace existing screening guidance or establish a new standard of care. The next milestone is evidence showing whether broader assessments identify relevant causes of weakness and whether acting on those findings improves mobility, daily function or other outcomes compared with current practice.
Key Questions
What does the paper propose about sarcopenia?
It argues that sarcopenia should be understood as involving the aging motor system, including the brain, spinal cord, nerves and muscles, rather than muscle loss alone.
Does the paper prove that muscle loss is not involved?
No. The authors do not say muscle is irrelevant. Their argument is that muscle loss explains only part of age-related weakness and should be considered alongside other factors affecting movement.
What might clinicians assess under the proposed approach?
The report describes looking at how quickly someone rises from a chair, steadiness during effort, hand dexterity and walking while talking, alongside existing measures such as grip strength and gait speed. These suggestions still need validation.
Has the proposed approach been shown to prevent falls?
No. The report says the suggested measures have not been shown to outperform existing screens on outcomes or cost. The paper calls for further studies and trials.
Source: rss
